Biosimilars present opportunity for PBMs

Pharmacy benefit managers are expected to update formularies next month regarding coverage of Johnson & Johnson's Remicade an -More

PCMA offers to work with FDA chief Scott Gottlieb to address the opioid crisis

Read the letter. -More

Reps. investigate possible shadow pricing of MS drugs

Reps.  -More

Mylan agrees to pay $465M to settle EpiPen misclassification claims

EpiPen maker Mylan agreed to pay $465 million as part of a final settlement deal with the Justice Department, resolving claim -More

HHS delays rule that would lower ceiling prices for 340B drug program

HHS has postponed until July 2018 the effective date of a new rule that would have reduced ceiling prices for medications pur -More

Pfizer's Besponsa price set at $168,300

Pfizer's Besponsa, or inotuzumab ozogamicin, was approved by the FDA as a treatment for adult patients with relapsed/refracto -More

Alexion adds patents to Soliris

Alexion has gained three new patents for its expensive biologic drug Soliris, or eculizumab, for paroxysmal nocturnal hemoglo -More

Long-acting Victoza outperforms Trulicity in head-to-head trial

Novo Nordisk's semaglutide, a long-acting version of Victoza, or liraglutide, reduced blood glucose levels and weight better  -More

There is no waste of any kind in the world that equals the waste from needless, ill-directed and ineffective motions.

Frank Bunker Gilbreth, engineer